163 related articles for article (PubMed ID: 36696472)
21. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
[TBL] [Abstract][Full Text] [Related]
22. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
García-Suárez J; de la Cruz J; Cedillo Á; Llamas P; Duarte R; Jiménez-Yuste V; Hernández-Rivas JÁ; Gil-Manso R; Kwon M; Sánchez-Godoy P; Martínez-Barranco P; Colás-Lahuerta B; Herrera P; Benito-Parra L; Alegre A; Velasco A; Matilla A; Aláez-Usón MC; Martos-Martínez R; Martínez-Chamorro C; Susana-Quiroz K; Del Campo JF; de la Fuente A; Herráez R; Pascual A; Gómez E; Pérez-Oteyza J; Ruiz E; Alonso A; González-Medina J; Martín-Buitrago LN; Canales M; González-Gascón I; Vicente-Ayuso MC; Valenciano S; Roa MG; Monteliu PE; López-Jiménez J; Escobar CE; Ortiz-Martín J; Diez-Martin JL; Martinez-Lopez J;
J Hematol Oncol; 2020 Oct; 13(1):133. PubMed ID: 33032660
[TBL] [Abstract][Full Text] [Related]
23. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination.
Butt AA; Nafady-Hego H; Chemaitelly H; Abou-Samra AB; Khal AA; Coyle PV; Kanaani ZA; Kaleeckal AH; Latif AN; Masalmani YA; Bertollini R; Raddad LJA
Int J Infect Dis; 2021 Sep; 110():353-358. PubMed ID: 34375762
[TBL] [Abstract][Full Text] [Related]
24. Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis.
Tucker M; Azar MM; Cohen E; Gan G; Deng Y; Foppiano Palacios C; Malinis M
Transpl Infect Dis; 2022 Aug; 24(4):e13876. PubMed ID: 35684932
[TBL] [Abstract][Full Text] [Related]
25. Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.
Papagoras C; Zioga N; Papadopoulos V; Gerolymatou N; Kalavri E; Bounos C; Simopoulou T; Fragoulis GE; Panopoulos S; Fragiadaki K; Evangelatos G; Bournia VK; Arida A; Karamanakos A; Pappa M; Kravvariti E; Deftereou K; Kougkas N; Zampeli E; Kataxaki E; Melissaropoulos K; Barouta G; Panagiotopoulos A; Koutsianas C; Liossis SN; Georgiou P; Dimitroulas T; Tektonidou MG; Bogdanos DP; Elezoglou A; Voulgari PV; Sfikakis PP; Vassilopoulos D
Clin Rheumatol; 2023 Dec; 42(12):3375-3385. PubMed ID: 37731083
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.
Hasseli R; Richter JG; Hoyer BF; Lorenz HM; Pfeil A; Regierer AC; Schmeiser T; Strangfeld A; Voll RE; Krause A; Reckert S; Gräßler A; Saar P; Kapelle A; Backhaus M; Blank N; Henes J; Osiek S; Knothe A; Hoese G; Brandt-Jürgens J; Maltzahn A; Specker C; Müller-Ladner U; Schulze-Koops H; ;
RMD Open; 2023 Apr; 9(2):. PubMed ID: 37068915
[TBL] [Abstract][Full Text] [Related]
28. Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study.
Rooney A; Bivona C; Liu B; Streeter D; Gong H; Khan Q
J Hematol Oncol; 2022 May; 15(1):67. PubMed ID: 35597960
[TBL] [Abstract][Full Text] [Related]
29. Clinical Features and Outcomes of Hospitalized Adult Patients With Breakthrough COVID-19 Infections: A Propensity-Score-Matched Observational Study.
Niu J; Samuels S; Sareli C; Mayer D; Visbal A; Sareli AE
Am J Epidemiol; 2024 Feb; 193(2):285-295. PubMed ID: 37823271
[TBL] [Abstract][Full Text] [Related]
30. First-Generation SARS-CoV-2 Vaccines: A Comparative Analysis between Vaccinated and Unvaccinated Hospitalized Patients Infected with SARS-CoV-2.
Basnet A; Tamang B; Pokhrel N; Khadka S; Shrestha MR; Ghimire S; Prajapati R; Thapa S; Duwal Shrestha SK; Chand AB; Amatya I; Rai SK
Kathmandu Univ Med J (KUMJ); 2022; 20(79):316-322. PubMed ID: 37042373
[TBL] [Abstract][Full Text] [Related]
31. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
32. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.
Taquet M; Dercon Q; Harrison PJ
Brain Behav Immun; 2022 Jul; 103():154-162. PubMed ID: 35447302
[TBL] [Abstract][Full Text] [Related]
33. Association of Influenza Vaccination With SARS-CoV-2 Infection and Associated Hospitalization and Mortality Among Patients Aged 66 Years or Older.
Hosseini-Moghaddam SM; He S; Calzavara A; Campitelli MA; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2233730. PubMed ID: 36169955
[TBL] [Abstract][Full Text] [Related]
34. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient Clinical Outcome.
Robinson ML; Morris CP; Betz JF; Zhang Y; Bollinger R; Wang N; Thiemann DR; Fall A; Eldesouki RE; Norton JM; Gaston DC; Forman M; Luo CH; Zeger SL; Gupta A; Garibaldi BT; Mostafa HH
Clin Infect Dis; 2023 May; 76(9):1539-1549. PubMed ID: 36528815
[TBL] [Abstract][Full Text] [Related]
35. Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.
Oliva A; Cogliati Dezza F; Petrucci F; Romani FE; Morviducci M; Mirabelli FM; Cancelli F; Valeriani E; Marcelli G; Pugliese F; Turriziani O; Ricci P; Venditti M; Palange P; Mastroianni CM
Clin Exp Med; 2023 Oct; 23(6):2275-2285. PubMed ID: 36867292
[TBL] [Abstract][Full Text] [Related]
36. Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed.
Lee CM; Lee E; Park WB; Choe PG; Song KH; Kim ES; Park SW
J Korean Med Sci; 2022 Aug; 37(32):e252. PubMed ID: 35971766
[TBL] [Abstract][Full Text] [Related]
37. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
38. Chest CT features of COVID-19 in vaccinated versus unvaccinated patients: use of CT severity score and outcome analysis.
Masci GM; Izzo A; Bonito G; Marchitelli L; Guiducci E; Ciaglia S; Lucchese S; Corso L; Valenti A; Malzone L; Pasculli P; Ciardi MR; La Torre G; Galardo G; Alessandri F; Vullo F; Manganaro L; Iafrate F; Catalano C; Ricci P
Radiol Med; 2023 Aug; 128(8):934-943. PubMed ID: 37354309
[TBL] [Abstract][Full Text] [Related]
39. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
